RNAC Q1 2023 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$218M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M-82.5% YoY

Gross Profit

-$13M-213.6% margin

Operating Income

-$18M-309.5% margin

Net Income

-$22M-364.8% margin

EPS (Diluted)

$-4.24

QoQ Revenue Growth

-64.6%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$156M

Total Liabilities

$81M

Stockholders' Equity

$75M

Cash & Equivalents

$126M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$34M	-82.5%
Gross Profit	-$13M	$33M	-138.0%
Operating Income	-$18M	$11M	-270.6%
Net Income	-$22M	$29M	-175.3%